Who
Seshu Tyagarajan
Chief Technology Officer
Company insider
Files Form 4 as: Chief Technology Officer, Candel Therapeutics.
In numbers
- Trades disclosed
- 25
- Buys
- 2
- Sells
- 9
- Bought
- $25K
- Sold
- $1.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Apr 2022
- Last trade
- 17 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 19 Aug 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $84K7,000 at $12.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $84K7,000 at $12.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $70K7,000 at $10.02 | filing |
| 29 Jun 2026filed 1 Jul 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $70K7,000 at $10.02 | filing |
| 26 Jan 2026filed 28 Jan 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —154,000 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —154,000 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code A | $25K5,353 at $4.67 | filing |
| 17 Mar 2025filed 20 Mar 2025 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 17 Mar 2025filed 20 Mar 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code M | $26K20,000 at $1.29 | filing |
| 17 Mar 2025filed 20 Mar 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $276K31,278 at $8.82 | filing |
| 17 Mar 2025filed 19 Mar 2025 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $276K31,278 at $8.82 | filing |
| 12 Feb 2025filed 14 Feb 2025 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 15 Jan 2025filed 17 Jan 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $104K14,322 at $7.23 | filing |
| 8 Jan 2025filed 10 Jan 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $120K14,545 at $8.22 | filing |
| 29 Nov 2024filed 3 Dec 2024 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $93K20,392 at $4.56 | filing |
| 17 Jul 2024filed 19 Jul 2024 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $96K14,851 at $6.47 | filing |
| 11 Jul 2024filed 15 Jul 2024 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $80K13,330 at $5.97 | filing |
| 28 Nov 2023filed 30 Nov 2023 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K17,328 at $0.90 | filing |
| 26 Nov 2023filed 28 Nov 2023 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code A | —104,516 at $0.00 | filing |
News
Candel Therapeutics Appoints Maria Ostrovsky as General CounselCADL · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Seshu Tyagarajan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.